Open Orphan plc (AIM: ORPH), is a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials.
announces that further to the appointment of Liberum Capital Limited (“Liberum”) as its Nominated Adviser and Joint Broker on28 April 2022, Liberum has confirmed that it has completed its due diligence.
End……….
We know that there had been some misunderstanding following our announcement on 28 April 2022 announcing the appointment of Liberum as our new Nominated Adviser. As mentioned at the time, the wording included in our announcement was standard wording for all former clients of Arden Partners given the relatively short notice provided to the Company to appoint and complete take-on of a new Nominated Adviser following the recommended takeover of Arden Partners by the Ince Group plc and their subsequent loss of nomad status.
As expected, the due diligence has been completed quickly and well ahead of the deadline given by the London Stock Exchange. We are delighted to be working with such a prestigious investment bank as Liberum and look forward to continuing to grow the business as we expand our offering to drive new revenue streams.
For further information please contact:
Open Orphan plc
+44 20 7756 1300
Yamin Khan, Chief Executive Officer
